[Novel therapies for MDS and future prospects].

Abstract excerpt

Myelodysplastic syndromes (MDS) are clonal diseases resulting from the accumulation of genetic mutations. In general, MDS is categorized into two risk groups, with management and treatment varying significantly based on this classification. Over the past two decades, allogeneic transplantation and hypomethylating agents (HMAs) have become the standard of care and remain crucial for higher-risk MDS. Unfortunately,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Molecular Targeted Therapy
• Share to Mutation
• Share to Myelodysplastic Syndromes